ArticleHematology. American Society of Hematology. Education Program2023
The role of emicizumab in acquired hemophilia A.
Article in Hematology. American Society of Hematology. Education Program, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.Blood advances · 2025Trial
- Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A.Blood vessels, thrombosis & hemostasis · 2026Article
- Acute Groin Pain Revealing Acquired Hemophilia A: A Case Report of Spontaneous Iliopsoas Hematoma.Cureus · 2026Article
- Pregnancy-Associated Acquired Hemophilia A (PA-AHA) Treated Successfully With the Factor-Mimetic Bispecific Antibody Emicizumab: A Case Report and Literature Review.Case reports in hematology · 2026Article
- Emicizumab as first-line therapy in acquired hemophilia A.Research and practice in thrombosis and haemostasis · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia is a rare bleeding disorder that predominantly affects older people with potential underlying comorbidities, including cardiovascular and thrombotic risk factors. The current standard therapies with hemostatic agents for acute bleeding and immunosuppression often require inpatient management, are not approved for routine bleeding prophylaxis, and contribute to the high mortality in this population. Emicizumab is a factor VIII (FVIII) mimetic approved for bleeding prophylaxis in congenital hemophilia A with and without FVIII inhibitors. Given subcutaneously, it may allow easier outpatient bleeding prophylaxis and reduce intensity of immunosuppression. This article summarizes the currently available data on the efficacy and safety of emicizumab in acquired hemophilia A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.